PRMT5 and breast carcinoma: We show here evidence that PRMT5 inhibitors suppress DDR gene expression through epigenetic and AS mechanisms and enhance the sensitivity of ovarian and breast cancers to chemotherapy and PARP inhibitors in vitro and in vivo.